You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

~ Buy the GALAFOLD (migalastat hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR GALAFOLD

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Galafold

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00214500 ↗	A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease	Completed	Amicus Therapeutics	Phase 2	2006-01-02	Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00283933 ↗	A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease	Completed	Amicus Therapeutics	Phase 2	2006-05-09	Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00283959 ↗	A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease	Completed	Amicus Therapeutics	Phase 2	2006-06-27	Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) and how migalastat works in participants with Fabry disease.
NCT00304512 ↗	A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease	Completed	Amicus Therapeutics	Phase 2	2006-09-07	Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
NCT00526071 ↗	Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study	Terminated	Amicus Therapeutics	Phase 2	2007-09-17	Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
NCT00925301 ↗	Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease	Completed	Amicus Therapeutics	Phase 3	2009-10-23	The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Galafold

Condition Name

Chart
Table

Condition Name for Galafold
Intervention	Trials
Fabry Disease	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Galafold
Intervention	Trials
Fabry Disease	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Galafold

Trials by Country

Map
Table

Trials by Country for Galafold
Location	Trials
United States	61
Australia	16
Canada	10
United Kingdom	8
France	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Galafold
Location	Trials
Georgia	8
New York	6
Virginia	5
Kansas	5
Texas	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Galafold

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Galafold
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Galafold
Clinical Trial Phase	Trials
Completed	8
Terminated	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Galafold

Sponsor Name

Chart
Table

Sponsor Name for Galafold
Sponsor	Trials
Amicus Therapeutics	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Galafold
Sponsor	Trials
Industry	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.